Enhancing Prescription Drug Innovation and Adoption
- 21 June 2011
- journal article
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 154 (12), 833-837
- https://doi.org/10.7326/0003-4819-154-12-201106210-00012
Abstract
The adoption and use of a new drug would ideally be guided by its innovation and cost-effectiveness. However, information about the relative efficacy and safety of a drug is typically incomplete even well after market entry, and various other forces create a marketplace in which most new drugs are little better than their older counterparts. Five proposed mechanisms are considered for promoting innovation and reducing the use of therapies ultimately found to offer poor value or have unacceptable risks. These changes range from increasing the evidence required for U.S. Food and Drug Administration approval to modifying the structure of drug reimbursement. Despite the challenges of policy implementation, the United States has a long history of successfully improving the societal value and safe use of prescription medicines.Keywords
This publication has 30 references indexed in Scilit:
- Using Market-Exclusivity Incentives to Promote Pharmaceutical InnovationNew England Journal of Medicine, 2010
- How Medicare Could Use Comparative Effectiveness Research In Deciding On New Coverage And ReimbursementHealth Affairs, 2010
- Comparative Effectiveness and Health Care Spending — Implications for ReformNew England Journal of Medicine, 2010
- Sources of drug information: FDA-approved labeling and other official FDA sourcesDermatologic Therapy, 2009
- Effects of Torcetrapib in Patients at High Risk for Coronary EventsNew England Journal of Medicine, 2007
- Do Newer Prescription Drugs Pay For Themselves? A Reassessment Of The EvidenceHealth Affairs, 2007
- Medicaid’s Prior Authorization Program And Access To Atypical Antipsychotic MedicationsHealth Affairs, 2007
- A comparative analysis of drug safety withdrawals in the UK and the US (1971–1992): Implications for current regulatory thinking and policySocial Science & Medicine, 2005
- Industry funding of the FDA: effects of PDUFA on approval times and withdrawal ratesNature Reviews Drug Discovery, 2005
- Some Factors to Consider when Using the Results of Economic Evaluation Studies at the Population LevelInternational Journal of Technology Assessment in Health Care, 1994